Matches in Wikidata for { <http://www.wikidata.org/entity/Q38068489> ?p ?o ?g. }
- Q38068489 description "article científic" @default.
- Q38068489 description "article scientifique" @default.
- Q38068489 description "articol științific" @default.
- Q38068489 description "articolo scientifico" @default.
- Q38068489 description "artigo científico" @default.
- Q38068489 description "artigo científico" @default.
- Q38068489 description "artigo científico" @default.
- Q38068489 description "artikel ilmiah" @default.
- Q38068489 description "artikull shkencor" @default.
- Q38068489 description "artículo científico" @default.
- Q38068489 description "artículu científicu espublizáu en 2012" @default.
- Q38068489 description "bilimsel makale" @default.
- Q38068489 description "scienca artikolo" @default.
- Q38068489 description "scientific article published on 17 December 2012" @default.
- Q38068489 description "scientific article published on 17 December 2012" @default.
- Q38068489 description "scientific article published on 17 December 2012" @default.
- Q38068489 description "vedecký článok" @default.
- Q38068489 description "vetenskaplig artikel" @default.
- Q38068489 description "videnskabelig artikel" @default.
- Q38068489 description "vitenskapelig artikkel" @default.
- Q38068489 description "vitskapeleg artikkel" @default.
- Q38068489 description "vědecký článek" @default.
- Q38068489 description "wetenschappelijk artikel" @default.
- Q38068489 description "wissenschaftlicher Artikel" @default.
- Q38068489 description "наукова стаття, опублікована в грудні 2012" @default.
- Q38068489 description "научная статья" @default.
- Q38068489 description "научни чланак" @default.
- Q38068489 description "מאמר מדעי" @default.
- Q38068489 description "مقالة علمية نشرت في 17 ديسمبر 2012" @default.
- Q38068489 description "বৈজ্ঞানিক নিবন্ধ" @default.
- Q38068489 name "Maintaining hemostasis in acquired von Willebrand syndrome: a review of intravenous immunoglobulin and the importance of rituximab dose scheduling" @default.
- Q38068489 name "Maintaining hemostasis in acquired von Willebrand syndrome: a review of intravenous immunoglobulin and the importance of rituximab dose scheduling" @default.
- Q38068489 type Item @default.
- Q38068489 label "Maintaining hemostasis in acquired von Willebrand syndrome: a review of intravenous immunoglobulin and the importance of rituximab dose scheduling" @default.
- Q38068489 label "Maintaining hemostasis in acquired von Willebrand syndrome: a review of intravenous immunoglobulin and the importance of rituximab dose scheduling" @default.
- Q38068489 prefLabel "Maintaining hemostasis in acquired von Willebrand syndrome: a review of intravenous immunoglobulin and the importance of rituximab dose scheduling" @default.
- Q38068489 prefLabel "Maintaining hemostasis in acquired von Willebrand syndrome: a review of intravenous immunoglobulin and the importance of rituximab dose scheduling" @default.
- Q38068489 P1433 Q38068489-44CC939E-5A06-4655-BC66-92261A268FF9 @default.
- Q38068489 P1476 Q38068489-C4899F65-9A67-415C-91DA-3510C8304E82 @default.
- Q38068489 P2093 Q38068489-63B89F5B-BDA0-4691-8A3F-5B9DF2BAF0B3 @default.
- Q38068489 P2093 Q38068489-A0491C83-7E6C-424B-9B26-BF4BA3C6A701 @default.
- Q38068489 P2860 Q38068489-134CD5D6-10A7-487A-8919-FB2F872DBC7B @default.
- Q38068489 P2860 Q38068489-3B3C6E0F-C64C-4BC6-AE7A-8B6F570FD9C3 @default.
- Q38068489 P2860 Q38068489-41742E3F-C565-469C-BD3E-5D9F22840EDB @default.
- Q38068489 P2860 Q38068489-4AE5F695-4485-4885-ACD3-1CE2609ED94D @default.
- Q38068489 P2860 Q38068489-5370AECE-C2FE-417B-9F34-F64D6346708B @default.
- Q38068489 P2860 Q38068489-544F95D5-A4E5-4BC7-8BE7-DBDCCFD15FCA @default.
- Q38068489 P2860 Q38068489-5E0D9621-0C10-4AA8-91EB-EF3B84FDE42E @default.
- Q38068489 P2860 Q38068489-73570381-7197-45DF-8BDF-C0F79BFF2876 @default.
- Q38068489 P2860 Q38068489-8AC8AA9B-874F-4B6F-8874-5868178C465D @default.
- Q38068489 P2860 Q38068489-8E997099-C294-4A2B-863B-349BF68F989B @default.
- Q38068489 P2860 Q38068489-8F5BDA34-7CC6-49AC-8C2E-29D9E332DC07 @default.
- Q38068489 P2860 Q38068489-8FDB4CCA-8255-497D-94C2-0BFF82B4C60F @default.
- Q38068489 P2860 Q38068489-98DC8FE0-F854-4191-898F-737CA77AC277 @default.
- Q38068489 P2860 Q38068489-9F19E32E-40DF-4674-A7C7-D42F0CE929DB @default.
- Q38068489 P2860 Q38068489-A95E89F8-A9C6-4672-96EF-739BCAA8D54E @default.
- Q38068489 P2860 Q38068489-B03AB43D-9AB8-4CC7-AEA5-020B3709BC7F @default.
- Q38068489 P2860 Q38068489-B2C70065-F6EF-43C4-A74F-C1FF3E9014F6 @default.
- Q38068489 P2860 Q38068489-B7DE4B6A-5A69-4ABE-ADC9-AA528931630B @default.
- Q38068489 P2860 Q38068489-B99F0ED8-E402-4081-9D43-0E7FEC3A98B2 @default.
- Q38068489 P2860 Q38068489-BEA47BF0-DE42-4F31-BBE5-36070B6654E5 @default.
- Q38068489 P2860 Q38068489-CC961F6A-DB4B-4671-9664-65EFFCC54721 @default.
- Q38068489 P2860 Q38068489-D3881AB0-EEF1-455A-B894-6E725F6926A0 @default.
- Q38068489 P2860 Q38068489-D48556AE-5E51-4061-868B-2C63182324D1 @default.
- Q38068489 P2860 Q38068489-E23BB8EA-0126-4940-BA5C-04047D0F44FC @default.
- Q38068489 P2860 Q38068489-F9094A5E-5D84-4871-B106-8EE4C5777749 @default.
- Q38068489 P2860 Q38068489-FBAA5227-23B1-4678-8B0F-1B063FEE0230 @default.
- Q38068489 P304 Q38068489-2C636360-2307-44D2-8722-1CA511A5F5F4 @default.
- Q38068489 P31 Q38068489-68FD8BB4-1BF3-4D38-A270-AFA872FF61F5 @default.
- Q38068489 P31 Q38068489-b2847f7a-1c51-4b6f-be04-c55a92061119 @default.
- Q38068489 P356 Q38068489-DDB713A7-ACA5-4644-8959-77AA7B6644EC @default.
- Q38068489 P433 Q38068489-064011BC-0130-4CCE-BBCE-B406F125EE10 @default.
- Q38068489 P478 Q38068489-CCD7C62E-1357-482D-B351-0458342536E5 @default.
- Q38068489 P577 Q38068489-9FFEF61E-8ABC-409B-A522-87C215963D4C @default.
- Q38068489 P698 Q38068489-31C55ABA-0F95-46DC-B192-1A47A44DDA2A @default.
- Q38068489 P921 Q38068489-5E542BCB-847E-4EED-8F3D-1FF5ABB7F517 @default.
- Q38068489 P921 Q38068489-A814283F-5A6D-4ADC-BD5F-1DA5E17CC028 @default.
- Q38068489 P356 TRF.12017 @default.
- Q38068489 P698 23252513 @default.
- Q38068489 P1433 Q15758500 @default.
- Q38068489 P1476 "Maintaining hemostasis in acquired von Willebrand syndrome: a review of intravenous immunoglobulin and the importance of rituximab dose scheduling" @default.
- Q38068489 P2093 "Douglas E Gladstone" @default.
- Q38068489 P2093 "Jennifer A Kanakry" @default.
- Q38068489 P2860 Q33370863 @default.
- Q38068489 P2860 Q33379107 @default.
- Q38068489 P2860 Q33391903 @default.
- Q38068489 P2860 Q33393696 @default.
- Q38068489 P2860 Q33397849 @default.
- Q38068489 P2860 Q33771413 @default.
- Q38068489 P2860 Q34106965 @default.
- Q38068489 P2860 Q34540339 @default.
- Q38068489 P2860 Q34805491 @default.
- Q38068489 P2860 Q35094919 @default.
- Q38068489 P2860 Q36113634 @default.
- Q38068489 P2860 Q36812703 @default.
- Q38068489 P2860 Q37511516 @default.
- Q38068489 P2860 Q37871732 @default.
- Q38068489 P2860 Q37900875 @default.
- Q38068489 P2860 Q40020213 @default.
- Q38068489 P2860 Q43982844 @default.